Purpose: Endometrial cancer (EC) is the sixth most common malignancy among females worldwide. Due to limited therapeutic options, treatment of advanced or recurrent disease is associated with poor outcomes. The aim of this study was to describe the real-world treatment of patients with advanced or recurrent EC who received a systemic treatment following platinum-based chemotherapy.
View Article and Find Full Text PDFThis observational study assessed functional ability in patients treated with modified-release prednisone under conditions of normal clinical practice. Patients treated with modified-release prednisone were observed over 9 months. The primary outcome measure was the change from baseline total score using the Questionnaire on Activity Status (QAS); total QAS score ranges from 0 (severely impaired) to 100 (completely unimpaired).
View Article and Find Full Text PDFBackground: The Patient Benefit Index (PBI) is a recently developed instrument to assess patient satisfaction with treatment. It has been applied to only a limited number of psoriasis patients.
Objective: Characterization of patient-reported outcomes (PRO) in patients with moderate to severe psoriasis.
Cutaneous malignant melanoma is an aggressive disease of poor prognosis. Clinical and experimental studies have provided major insight into the pathogenesis of the disease, including the functional interaction between melanoma cells and surrounding keratinocytes, fibroblasts, and immune cells. Nevertheless, patients with metastasized melanoma have a very poor prognosis and are largely refractory to clinical therapies.
View Article and Find Full Text PDFEndometrial tissue inhibitors of metalloproteinases (TIMPs) appear to play an essential role during early implantation by modulating the invasiveness of the trophoblast. The expression of TIMP-1, TIMP-2 and TIMP-3 in human endometrial stromal cells (ESC) was investigated during decidualization . Endometrial stromal cells were isolated from hysterectomy specimens from premenopausal women undergoing surgery for benign reasons.
View Article and Find Full Text PDFObjective: To investigate whether human endometrial stromal cells (ESCs) express the interferon-gamma-receptor (IFN-gamma R) and whether the process of decidualization or human chorionic gonadotropin (hCG) regulate the IFN-gamma R and its signaling pathway.
Design: In vitro experiment.
Setting: Research laboratory at a medical university center.
Objective: To investigate the influence of hCG on trophoblastic matrix metalloproteinases (MMPs) -2 and -9 as well as endometrial tissue inhibitor of metalloproteinases (TIMPs) -1, -2, and -3.
Design: In vitro experiment.
Setting: Research laboratory at a university medical center.
The subtle interaction between the implanting embryo and the maternal endometrium plays a pivotal role during the process of implantation. Human endometrial stromal cells (ESCs) express Fas and the implanting trophoblast cells secrete Fas ligand (FASLG, FasL), suggesting a possible role for Fas-mediated signaling during early implantation. Here we show that ESCs are primarily resistant to Fas-mediated apoptosis independently of their state of hormonal differentiation.
View Article and Find Full Text PDFRecent data clearly show that hCG, as one of the first hormonal signals of the embryo, is involved in the modulation of endometrial receptivity in the secretory phase. Here we report a significant dose- and time-dependent inhibition of insulin-like growth factor-binding protein-1 and prolactin by hCG in human endometrial stromal cells after decidualization in vitro-findings that further underline the role of hCG in the endometrial milieu during early implantation.
View Article and Find Full Text PDF